Best EBs in Healthcare (NYC)

Saw a post about this for London, but as an incoming summer at a mid-tier BB healthcare group, curious about how EBs in NYC have done in the space. I'm definitely looking at lateraling as a future possibility and would love to only work in the advisory space (debt/equity processes don't interest me as much).

 

That is nonsense saying no one else is worth talking about from a boutique perspective.

Evercore has an excellent HC group.

PWP is very strong in medtech + diagnostics but those are definitely smaller spaces than the biotech/pharma world.

Lazard and PJT also have reputable HC teams.

After Centerview is JPM and probably GS.

Then you have MS and the boutiques you named if you really want to talk about HC.

 

Not even in the space but had a friend at evercore who did HC and even he said CVP was a clear cut winner in the space (specifically for biotech I'd say at the very least)

 
Most Helpful

CenterView is obviously great in pharma and also do good in HC services (including some
HCIT) but they don’t do med tech (Cantel was done by pharma guys). Evercore pharma kind of disappeared lately until GW deal. I don’t think their services team did any deals last year? They don’t do med tech. Guggenheim does all 3 and best med tech team on street. Pwp only seem to do med tech. Moelis more services focused and just lost the MD for half the business. Other half is dental, derm type covid impact PPM business. They don’t do as much pharma / med tech. Lazard is in some huge deals but not as much in volume. In all these banks, the sub vertical teams (and often MDs) run their own empire (vs a large HC group like at a BB). 

 

SVB Leerink just hired like 10 of the best HC bankers on the street. They will be a HC EB by EOY.

 

While the medtech team at Gugg is well respected as a top team. They also work ridiculous hours and have one of the worst cultures at the bank if not the worst (I’m at Gugg but in a different vertical). Their group heads are not in NYC as they have so much clout they cannot be bothered to come back. Two live in Florida and the other is in Texas building a mansion. This creates an odd culture where the physical in office team is just a bunch of analysts and the occasional associate/VP. They had a huge exodus last year post bonus where they were left with 0 Vps and 0 Associates. Currently more than 50% of the team are laterals.Guggenheim has become a very large firm in recent years, now over 800 bankers. A lot of the groups tend to hang out with one another, and analysts often have a lot of friends in other groups whom we hang out with outside of work or during our downtime. The medtech group is truly an animal of their own. I would say the best way to describe the juniors there are passionate hardos, not necessarily in a bad way, but it can def be intense. The sort who could go home to wfh after 7pm but choose to stay in the office and only talk about their projects during lunch and happy hours. They’re a bit siloed in, both culturally and socially. But hey, that works for some people. They’ll probably make more than me this year and close more transactions, but we do more than enough good deal flow that I don’t mind.

 

For Med Devices, hands down Guggenheim. Biotech is heavily dominated by CVP with latter podium places held by a mix of Evercore, Guggenheim, PWP and PJT. Moelis doesn't do much biotech as they're mostly on sponsor backed service deals and Lazard has mostly made their name off services and HCIT deals although they are getting into the mix as well.

For the BBs biotech is the bread and butter of JPM given they host a conference every January where everyone who is a somebody shows up to discuss deal making and their latest research. GS does well in this space as well, but they operate a more holistic HC practice where there is an equal focus on services and biotech (not much MedTech activity from what I've seen). MS/BAML from a fee standpoint are tied for 3rd. 

 

Ab veritatis culpa et sed porro sint quo. Dolorem debitis saepe enim illo autem velit nihil. Ipsum omnis impedit commodi a sed. Debitis aut explicabo sed nostrum quibusdam perspiciatis vel.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Lazard Freres No 98.8%
  • Goldman Sachs 18 98.3%
  • Harris Williams & Co. New 97.7%
  • JPMorgan Chase 04 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (20) $385
  • Associates (90) $259
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (67) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
kanon's picture
kanon
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.8
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”